Liviniti, a national leader in PBM transparency and prescription drug savings, recently announced its collaboration with the precision medicine company, BlueGenes, offering members access to cutting-edge pharmacogenomic (PGx) testing. BlueGenes’ patent-pending technology integrates seamlessly with Liviniti as well as electronic medical records to apply genetic data to clinical prescribing decisions in real time.
Advancement in PGx testing is good news for plan sponsors and patients living with complex, chronic conditions. Liviniti will have integrated BlueGenes PGx testing available to clients who choose to include it in their benefit plans.
“With this approach, healthcare providers gain access to additional insights that can help inform treatment decisions and support more personalized patient care from the start of therapy,” says Steven T. Boyd, EVP, Business Development, Liviniti. “Guided by their own DNA, patients start with the medication that will work best for them, avoiding side effects, reducing waste and getting to appropriate treatment faster.”
As an innovative force for change, Liviniti is dedicated to moving beyond the status quo to shape the future of pharmacy benefits for the better, and PGx testing is part of that future. “Our collaboration with BlueGenes is just one example of our commitment to powerful offerings that improve cost and health outcomes,” Steve adds.
“BlueGenes is excited to collaborate with Liviniti to deliver life-saving technology to its members,” said Nick Glimcher, CEO of BlueGenes. “Our platform makes pharmacogenetics actionable, ensuring that patients get the right drug the first time. This collaboration exemplifies a shared vision to leverage genetic insights at the point of care, transforming how health plans approach medication management. By bringing together BlueGenes’ PGx expertise and Liviniti’s PBM capabilities, this approach will help ensure that precision medicine becomes the standard of care, improving lives while controlling costs.”
BlueGenes is committed to revolutionizing medication management and improving patient outcomes. The company distinguishes itself from competitors by offering real-time claim reviews and enabling providers to make informed clinical decisions at the point of prescribing, as well as supporting notification at the point of sale. Unlike traditional paper or digital tests that require manual review with each prescription, BlueGenes automates the process, ensuring timely and accurate application of genetic data.
For more similar news on collaborations, check out the links below:
Revo Sunglasses and Renan Ozturk Collaborate on the Revo x Reo Collection: Glacier Glass Innovation
Aimotion and Google Cloud Collaborate to Scale AI-Driven Automotive Marketing Globally
H&M HOME and Kelly Wearstler Announce Full Global Collaboration
